Home
Resource
Dose finding methods based on cure rate model in phase I cancer clinical trials
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(1.34 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Chen, Menghui. Dose finding methods based on cure rate model in phase I cancer clinical trials. Retrieved from https://doi.org/doi:10.7282/T3TH8PHR

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleDose finding methods based on cure rate model in phase I cancer clinical trials
NameChen, Menghui (author); LIN, YONG (chair); Shih, Weichung Joe (internal member); Kim, Sinae (internal member); Wu, Yujun (outside member); Rutgers University; Graduate School - New Brunswick
Date Created2015
Other Date2015-05 (degree)
SubjectStatistics and Biostatistics, Clinical trials, Cancer--Research, Cancer--Treatment, Drugs--Dose-response relationship
Extent1 online resource (xviii, 159 p. : ill.)
DescriptionThe main goal of a Phase I cancer clinical trial is to identify the maximum tolerated dose (MTD) of a new drug having acceptable dose-limiting toxicity (DLT). Two main model-based designs are continual reassessment method (CRM) (O’Quigley et al., 1990) and escalation with overdose control (EWOC) (Babb et al., 1998). Most of the designs are based on the binary toxic outcome. The occurrence of DLT is assessed over a predefined time window, and complete follow-up of the current patient is required to fit the model. Information is lost by categorizing time to DLT to a binary variable and might lead to a poor estimate of MTD. Trials might have to suspend accrual to obtain complete data and lead to long trial durations and complicate administrative burdens. Some methods have been proposed to incorporate the time-to-DLT using a weight function, such as TITE-CRM by Cheung and Chappell (2000) and TITE-EWOC by Mauguen et al. (2011). A better approach would be to model the time-to-DLT data directly for patients who will experience the DLT and to separate these patients from those who will never experience the DLT given a specific dose. This approach can be based on the well-studied cure model, a type of mixture model. This mixture model seems to be more appropriate for dose finding in Phase I cancer studies when the time-to-DLT is incorporated. In this thesis, we will develop a Bayesian design framework based on cure model approach to incorporate the time-to-DLT and will extend the current model-based designs such as CRM, EWOC or the hybrid design (Chu et al., 2009) to incorporate the time-to-DLT event. We will call such design as CATE design for Cure rate model Approach for Time-to-DLT Event. To evaluate performance of CATE designs, extensive simulation studies had been conducted and the results shows that CATE designs outperform the existing designs for phase I cancer clinical trials.
NotePh.D.
NoteIncludes bibliographical references
Noteby Menghui Chen
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3TH8PHR
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024